Regeneron Pharmaceuticals, Inc. REGN

REGN Company Overview

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases. The company operates primarily in the biopharmaceutical and biotechnology industries, with a strong emphasis on genetic medicine, monoclonal antibodies, and biologics. Regeneron’s core revenue drivers are its proprietary antibody-based therapies, developed using its internal research platforms and brought to market through a combination of wholly owned products and strategic collaborations.

Regeneron serves global healthcare markets, primarily addressing ophthalmology, immunology, oncology, cardiovascular disease, infectious diseases, and rare genetic disorders. Its competitive positioning is driven by its vertically integrated R&D model, long-term investment in genetics research, and proprietary platforms such as VelociSuite technologies. Founded in 1988, Regeneron evolved from a research-focused startup into a large-cap biotechnology leader through sustained internal innovation, selective partnerships, and successful commercialization of blockbuster therapies.